36 



Mr. Kessler. Mr. Chairman, I would be very happy to work with 

 the committee. I am reluctant to do this today. Certainly if the 

 committee so instructs, we will be happy to provide you with infor- 

 mation. 



The issues that we are addressing today are general issues about 

 nicotine in cigarettes. I certainly don't want to — I understand the 

 problem of not releasing the name is that I may, unfortunately, 

 cast aspersions on other companies; and again, we will be happy 

 to provide all the information to you, Mr. Chairman. I think that 

 it is for your review. You can investigate further. You can see what 

 the facts that we have are, and determine whatever intent may fol- 

 low. 



Mr. Waxman. We will work with you to receive that material, 

 but you know of a study. You didn't learn of this through a con- 

 fidential means, did you? You know of a study that was sponsored 

 by the tobacco industry that was supposed to go into publication 

 and wasn't? 



Mr. Kessler. We have a letter from an editor that states what 

 I told you. 



Let me also just allow Dr. Henningfield — we also have 

 confirmation 



Mr. Waxman. Dr. Kessler, was this sponsored by the industry or 

 was it sponsored by a cigarette company? 



Mr. Kessler. It was a cigarette company. 



Mr. Waxman. And why can't we know the name of that com- 

 pany? 



Mr. Kessler. Again, Mr. Chairman, I would be happy to work 

 with you and give you our documents. I am not prepared at this 

 time to do that. I don't want today — I cannot come here to talk 

 about it. I was very careful in my presentation not to focus on spe- 

 cific brands or specific companies, and I would really rather not get 

 into that today. 



Again, we would be happy to give the committee the information, 

 and certainly you can do whatever the committee would like to do 

 with it. 



Mr. Waxman. I have run out of time. Do you have something 

 briefly to add? Maybe we will come back to you. 



Mr. Henningfield. I could just confirm that in fact in the early 

 1980's a number of us in the field were aware that one of the to- 

 bacco companies was sponsoring such drug self-administration re- 

 search. One of the tobacco company investigators sent me one of 

 the resulting manuscripts. This is something that is often done by 

 scientists; they exchange manuscripts and to let others know what 

 they are doing in the field. 



I had marked it in my files as an unpublished manuscript, and 

 therefore would not have cited the manuscript in my own literature 

 reviews. When I called the investigator to ask him what the status 

 of it is and if I could cite it in my literature reviews, he told me 

 that he would not be able to publish it, so that I would not be able 

 to cite it. Furthermore his words, to the best of my recollection, 

 were that the lawyers of the company had discovered that the in- 

 vestigators and colleagues were doing this work and that it showed 

 that nicotine looked like heroin, and therefore that such work 

 shouldn't be going on and it should not be published. 



